US2003166896A1PendingUtilityA1

Base-modified enzymatic nucleic acid

55
Assignee: RIBOZYME PHARM INCPriority: Oct 15, 1992Filed: Jun 13, 2002Published: Sep 4, 2003
Est. expiryOct 15, 2012(expired)· nominal 20-yr term from priority
Inventors:Nassim UsmanLeonid BeigelmanJames McswiggenAlex Karpeisky
C12N 2310/33C12N 2310/322C12N 2310/333C12N 2310/122C12N 2310/3535C12N 15/113C12N 2310/321C12N 2310/336C07K 14/005C12N 2770/28122C12N 2310/12C12N 2310/123C12N 2310/315C12N 15/85C12N 2310/334C12N 2310/121C12Q 1/6811C12N 2310/3533C07H 21/00C12N 2770/00022C12N 2310/335C12Q 1/701C12N 2310/3531C07H 19/06C12N 2310/3521C12N 15/86
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Method to produce a more active ribozyme by introducing a modified base into a substrate binding arm of the ribozyme or its catalytic core.

Claims

exact text as granted — not AI-modified
1 . A compound having the general formula:  
       
         
           
           
               
               
           
         
       
       wherein DMT is dimethoxytrityl.  
     
     
         2 . A compound having the general formula:  
       
         
           
           
               
               
           
         
       
       wherein R 1  is H or acetyl and DMT is dimethoxytrityl.  
     
     
         3 . A polynucleotide comprising one or more nucleotides having the general formula:  
       
         
           
           
               
               
           
         
       
     
     
         4 . A polynucleotide comprising one or more nucleotides having the general formula:  
       
         
           
           
               
               
           
         
       
       wherein R 1  is H or acetyl.  
     
     
         5 . The compound of  claim 1 , wherein said compound is used to synthesize a polynucleotide.  
     
     
         6 . The compound of  claim 2 , wherein said compound is used to synthesize a polynucleotide.  
     
     
         7 . The polynucleotide of  claim 3 , wherein said polynucleotide is an enzymatic nucleic acid.  
     
     
         8 . The polynucleotide of  claim 4 , wherein said polynucleotide is an enzymatic nucleic acid.  
     
     
         9 . A nucleoside phosphoramidite having a 6-methyl uridine base.  
     
     
         10 . A nucleoside phosphoramidite having a 6-methyl cytidine base.  
     
     
         11 . The nucleoside phosphoramidite of  claim 9 , further comprising a 5′-O-dimethoxy trityl (DMT) group.  
     
     
         12 . The nucleoside phosphoramidite of  claim 10 , further comprising a 5′-O-dimethoxy trityl (DMT) group.  
     
     
         13 . The nucleoside phosphoramidite of  claim 9 , further comprising a 2′-O-tert-butyl dimethylsilyl (TBDMS) group.  
     
     
         14 . The nucleoside phosphoramidite of  claim 10 , further comprising a 2′-O-tert-butyl dimethylsilyl (TBDMS) group.  
     
     
         15 . The nucleoside phosphoramidite of  claim 9 , wherein said nucleoside phosphoramidite is used to synthesize a polynucleotide.  
     
     
         16 . The nucleoside phosphoramidite of  claim 10 , wherein said nucleoside phosphoramidite is used to synthesize a polynucleotide.  
     
     
         17 . The nucleoside phosphoramidite of  claim 15 , wherein said polynucleotide is an RNA polynucleotide.  
     
     
         18 . The nucleoside phosphoramidite of  claim 16 , wherein said polynucleotide is an RNA polynucleotide.

Join the waitlist — get patent alerts

Track US2003166896A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.